Q-omics provides the consensus-scored NRROS profile across patient tissues and cancer cell-line models. NRROS expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NRROS is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NRROS RNA expression shows 19,599 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where NRROS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRROS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRROS survival associations across molecular data types. NRROS RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRROS RNA expression–survival associations across cancer types. High NRROS expression shows favorable associations in HNSC, UVM, KIRC, PAAD, LUAD and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NRROS RNA expression.
This table summarizes NRROS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NRROS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRROS shows lower tumor expression in LUAD, LUSC, KICH and BRCA and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher NRROS RNA expression in tumor versus normal tissue (log2 FC = +1.220, t-test p < 0.001).
This table shows molecular features associated with NRROS in patient tissues and cancer cell lines. In patient samples, NRROS shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NRROS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
